6 Results for "

CLK1-IN-1

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "CLK1-IN-1" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-103082
CAS No.: 2123491-32-5
Purity:  98.55%
Target:  

CDK

Research Areas:  

Others

CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM.
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-15338
CAS No.: 719277-26-6
Purity:  99.57%
Target:  

CDK

Research Areas:  

Cancer

TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
loading...
    loading...
Cat. No.: HY-15338A
CAS No.: 300801-52-9
Target:  

CDK

Research Areas:  

Cancer

(E/Z)-TG003 is a racemic compound of (Z)-TG003 and (E)-TG003. (Z)-TG003 is a potent inhibitor of Clk1/Sty; inhibits Clk1 and Clk4 with IC50 values of 20 and 15 nM, respectively .
loading...
    loading...
Cat. No.: HY-103082R
CAS No.: 2123491-32-5
Target:  

Reference Standards CDK

Research Areas:  

Others

CLK1-IN-1 (Standard) is the analytical standard of CLK1-IN-1 (HY-103082). This product is intended for research and analytical applications. CLK1-IN-1 is a potent and selective of Cdc2-like kinase 1 (CLK1) inhibitor, with an IC50 of 2 nM.
loading...
    loading...
Cat. No.: HY-E70691
Target:  

CDK

Research Areas:  

Cancer

CLK1 is one of the dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 Recombinant Human Active Protein Kinase is a recombinant CLK1 protein that can be used to study CLK1-related functions .
loading...
    loading...
Cat. No.: HY-131909
CAS No.: 2226742-61-4
Research Areas:  

Cancer

CJ-2360 is a potent and orally active ALK inhibitor with IC50s of 2.2, 4.0, 8.8, 6.3, and 8.9 nM against wild-type ALK and F1197M, G1269A, L1196M, and S1206Y ALK mutants, respectively. CJ-2360 displays potent inhibitory activity against two clinically reported ALK mutants (C1156Y and L1196M) and a few other kinases (LTK, MERTK, CLK1, DAPK1, and DAPK2) among the 468 kinases evaluated .
loading...
    loading...